Atlas Trials

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Clinical trial NCT01213732 · COMPLETED

Trial details

NCT number
NCT01213732
Sponsor
Philogen S.p.A.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Patients With Intransit Stage III/IV Melanoma
Start date
2008-10-01
Primary completion
2011-03-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.